Travere Therapeutics (TVTX) Insider Roy Baynes Buys $96K of Stock

Insider Buying and Selling at Travere Therapeutics, Inc.

Roy Baynes carried out a transaction involving 4,500 shares of Travere Therapeutics, Inc. (NasdaqGM: TVTX) on June 12, 2026. This filing follows other recent portfolio adjustments by Baynes, including a purchase of shares in Natera late last month. Market observers frequently monitor these transactions to gauge how insiders manage their personal holdings in the biotechnology sector.

Travere Therapeutics Stock Performance and Valuation

Travere Therapeutics shares recently traded around $53.80, remaining well above the 52-week low of $22.05 while holding below the peak of $68.73. The company carries a forward P/E ratio of 11.08, giving investors a metric to evaluate its projected profitability relative to its share price. The stock's 50-day moving average sits at $61.71, while the 200-day moving average rests at $43.89.

Recent Earnings and Financial Health

The biopharmaceutical firm reported annual revenue of $591.3 million alongside a revenue growth rate of 48.2%. Profitability metrics show a net margin of -7.35% and a return on equity of -2.36%, typical for a growing drug developer investing heavily in clinical trials. Investors will look toward the company's next earnings report scheduled for October 29, 2026, for further details on commercial uptake.

Analysts Set New Price Targets

Wall Street firms have kept a close eye on the company, maintaining an overall strong buy consensus across 14 analyst opinions with a mean price target of $74.21. On September 24, 2026, Guggenheim maintained its buy rating while adjusting its price target to $89.00 from $75.00. Earlier on September 22, 2026, Wedbush reiterated an outperform rating with a $76.00 target, and HC Wainwright & Co. reaffirmed a buy rating with a $67.00 target. Additional updates came in August, with Evercore ISI Group keeping its outperform rating and lifting its target to $78.00 on August 10, 2026. Canaccord Genuity maintained a buy rating on August 6, 2026, setting a $70.00 target, while Wedbush held an outperform rating with a $75.00 target on the same day. TD Cowen maintained a buy rating with a $75.00 target on August 5, 2026, and Citigroup kept a buy rating with an $85.00 target on the same day.

Overview of Travere Therapeutics Operations

Travere Therapeutics is a San Diego-based biopharmaceutical company focused on developing treatments for rare kidney and metabolic conditions. Its approved products include FILSPARI for IgA Nephropathy and Thiola for cystinuria, alongside clinical pipelines targeting focal segmental glomerulosclerosis and classical homocystinuria.

What to Watch Next for TVTX

Market participants will track upcoming regulatory updates and the October 29 earnings release for clues on commercial progress. Insider filings and further analyst adjustments will continue to shape sentiment around the rare disease specialist in the coming months.